Skip to main content

Advertisement

Table 3 Cox regression for time to first occurrence of DAIDS Grade 3 or 4 ALT and/or AST abnormalities in TPV/r-based and comparator PI/r- (CPI/r-) based cART RESIST patients

From: Hepatic profile analyses of tipranavir in Phase II and III clinical trials

Parameter HR1 (p-value) 95% Confidence Interval
Treatment group: 2.77 (<0.0001) 1.71, 4.48
   TPV/r v CPI/r   
HBV or HCV co-infection: 2.00 (0.0057) 1.22, 3.27
   yes vs. no   
ALT/AST at baseline: 2.05 (0.0709) 0.94, 4.48
   Grade ≥2 vs. ≤Grade 1   
CD4+ cells at baseline: 1.46 (0.0643) 0.98, 2.18
   >200 vs. ≤200 cells/mm3   
  1. 1 Hazard Ratio
  2. Model further controlled for sex, race and concurrent use of T-20 (none were statistically significant).